Quantitative functional assessment of gene therapeutics for Muscular Dystrophy
Dystrophin is a large cytoskeletal protein that makes a bridge between the cytoskeletal actin microfilaments in muscle cells and the extracellular matrix, through the Dystrophin-Dystroglycan complex located at the plasma membrane....
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MAGIC
Next-generation models and genetic therapies for rare neurom...
7M€
Cerrado
SCOPE-DMD
Consortium for Products across Europe in Duchenne Muscular D...
21M€
Cerrado
DMD2CURE
Correction of duplications in the DMD gene by a CRISPR Cas9...
185K€
Cerrado
DM1-MIRNA
New therapeutic targets for DM1 miRNAs analysis in DM1 dise...
100K€
Cerrado
circRNA4DMD
Circular RNA Therapeutics for Duchenne Muscular Dystrophy
3M€
Cerrado
ANTES
Accelerating Neuromuscular Treatment Selection
100K€
Cerrado
Información proyecto QUESTFORMD
Líder del proyecto
KINGS COLLEGE LONDON
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
232K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Dystrophin is a large cytoskeletal protein that makes a bridge between the cytoskeletal actin microfilaments in muscle cells and the extracellular matrix, through the Dystrophin-Dystroglycan complex located at the plasma membrane. This strong link is responsible for conferring resistance to muscle contraction. Duchenne Muscular Dystrophy (DMD) is an X-chromosome linked disease caused by a mutation on the Dystrophin gene that results in damage to muscle fibers. Affected individuals rarely live beyond the third decade of life. Gene therapy is being trialed to replace the mutant protein. Since Dystrophin is a large protein, proposed gene therapies employ truncated versions of Dystrophin. Therapy faces delays because of poor understanding of the protein stability and levels required for functional recovery in the in vivo context. This proposed project aims to explore how Dystrophin stability and turnover is modulated by its structural domains, taking advantage of cutting edge in vivo imaging techniques applied to the zebrafish model. Several truncated Dystrophin constructs, containing different combinations of specific rod regions, are used on trials. The hypothesis that these differ in their ability to replace natural Dystrophin will be tested. By imaging Dystrophin-GFP fusions after genetic manipulation of single cells in the live animal, we will determine Dystrophin dynamics and function in the living organism at the single cell level, leading to insights into cytoskeletal biology. We will test the ability of truncated human Dystrophins to rescue zebrafish dystrophin mutants and determine how much, and when, Dystrophin is required to rescue muscle structure and function. Our proposal strongly promotes transfer of knowledge between developmental biology and applied clinical research. The project will establish the applicant as a key member of a multidisciplinary international team aiming to develop time- and cost-effective initial screens for gene therapeutics.